Clinical Impact of New Data From Boston 2016
Source: 2016 Annual Meeting of the American Association for the Study of Liver Diseases*

Slideset

Clinical Impact of New Data From Boston 2016

In this downloadable slideset, expert faculty members Ira M. Jacobson, MD, and Stefan Zeuzem, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 581 KB
Date posted: 11/30/2016
  • Hepatitis B Reactivation: Sometimes Scratching the Surface May Be Better Than Getting to the Core

    Jordan J. Feld MD, MPH - 1/24/2017    3 comments / Last Comment: 5/6/2017
    Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.
  • Do HCV DAAs Increase HCC Recurrence Risk or Not?

    Paul Y. Kwo MD - 5/25/2017    7 comments / Last Comment: 6/27/2017
    Here’s my take on new data from EASL 2017.
  • How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management

    Mark S. Sulkowski MD - 1/31/2017    2 comments / Last Comment: 4/24/2017
    The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.
  • Why I am Encouraged by Data on NASH Management From the 2016 Boston Hepatology Meeting

    Brent A. Neuschwander-Tetri MD - 3/10/2017    
    The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.
  • EASL 2017: Emerging Therapies for Genotype 3 HCV

    Nancy Reau MD, FAASLD, AGAF - 5/12/2017    6 comments / Last Comment: 6/23/2017
    Genotype 3 HCV infection is concerning, not just because of its natural history but also because of its potential role in reinfection. New data from EASL offer promise for the treatment of this challenging patient population.